NEWS
Print Your Certificate
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
Fouad S Alchami
Sidra Medical and Research Center - - / Qatar
Others
AD Scientific Index ID: 4618048
-
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Fouad S Alchami's MOST POPULAR ARTICLES
1-)
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a …RH Jones, A Casbard, M Carucci, C Cox, R Butler, F Alchami, TA Madden, ...The Lancet Oncology 21 (3), 345-357, 20201202020
2-)
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cellsHC Chen, N Joalland, JS Bridgeman, FS Alchami, U Jarry, MWA Khan, ...Immunology and Cell Biology 95 (7), 620-629, 2017462017
3-)
Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through posttranslational downregulation of c-FLIPL Piggott, A Silva, T Robinson, A Santiago-Gómez, BM Simões, M Becker, ...Clinical Cancer Research 24 (10), 2452-2463, 2018482018
4-)
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION …RH Jones, M Carucci, AC Casbard, R Butler, F Alchami, CJ Bale, ...Journal of Clinical Oncology 37 (15_suppl), 1005-1005, 2019472019
5-)
Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesotheliomaFS Alchami, RL Attanoos, AR BamberJournal of Clinical Pathology 70 (2), 179-182, 2017332017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept